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Felix qui potuit rerum cognoscere causas
Happy is he who has been able to learn the causes of
things
––Virgil, Georgiche, II, 489
H ypertrophic cardiomyopathy (HCM) is a commoninherited cardiac disease defined clinically by the
presence of unexplained left ventricular (LV) hypertrophy
(LVH). In most patients, HCM is caused by mutations in genes
encoding proteins of the cardiac sarcomere.1–4 Symptoms
include dyspnea on exertion, fatigue, angina, atypical chest
pain, syncope, and palpitations. A significant proportion of
patients are asymptomatic throughout life and the diagnosis
often follows the incidental finding of abnormal ECG results or
the detection of a cardiac murmur. The natural history is
variable. Many patients have a normal life expectancy,
whereas others may experience disease progression with
profound exercise limitation, recurrent arrhythmias, and
premature death largely caused by heart failure.5,6 Sudden
cardiac death (SCD) is relatively rare, occurs more commonly
in young patients, and is mainly caused by ventricular
arrhythmias that can be effectively treated with an implan-
table cardioverter-defibrillator.7,8
HCM is a typical example of monogenic disease where a
single nucleotide mutation is sufficient to cause a complex
pathologic phenotype.9 Genetic testing identifies pathogenic
or likely pathogenic variants in 30% to 50% of patients with
HCM, and over 1 000 distinct mutations in genes encoding
11 different components of the sarcomere have been
identified.10–13 Using genetic testing to identify possible
mutations may help streamline family evaluation and longitu-
dinal follow-up.14 After 25 years of genetic testing, however,
we are still unable to predict phenotypes and outcomes from
a gene-based model. HCM is an extremely heterogeneous
disease with regard to clinical onset and presentation,
phenotype, and clinical course, even within the same
pedigree. Both penetrance and expressivity are thought to
be influenced by epigenetic and environmental mechanisms,
although the quality and extent of these interactions remain
elusive.15
In this review, we focus on the complex interplay between
genetics and potential modifiers of disease expression
including demographic features, physiological challenges such
as pregnancy and physical exercise, as well as comorbid
conditions. Some of the potential modifiers (Table 1) will be
used as examples to discuss gene–environment interaction in
this particular clinical setting.
Life Cycle
Age
Although age cannot be considered an environmental factor
sensu stricto, the effects of aging on the heart are
indisputable. In recent years, older patients with HCM have
been increasingly recognized because of greater awareness of
the disease and advances in cardiac imaging techniques.
Young patients appear to have a higher risk of arrhythmic
SCD, which is rare in those older than 60 years.16 Such an
inverse relationship between advanced age and SCD-related
risk in HCM inevitably affects management decisions, partic-
ularly regarding implantable cardioverter-defibrillator implan-
tation. Conversely, the burden of disease in terms of atrial
fibrillation and heart failure–related complications peaks in
patients aged 50 to 70 years and it may be attributable to
long-standing microvascular ischemia and progressive
myocardial fibrosis leading to remodeling of the left ventricle
and left atrial chambers.17 In this regard, while younger
patients rarely develop heart failure-related issues, an early
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onset of disease is associated with markedly increased risk of
HCM complications after midlife.17
Pregnancy
Pregnancy is characterized by significant physiological
changes in the cardiovascular system, including increases in
cardiac output, extracellular fluid volume and arterial compli-
ance, and reduction in blood pressure and total peripheral
resistance. Hormonal changes include increased levels of
estrogens and progesterone, which result in vasodilatation. A
substantial activation of the renin-angiotensin-aldosterone
system occurs early in pregnancy and results in increased
plasma volume.18 These physiological changes also affect the
heart, with significant increase in LV wall thickness and mass.
Preexisting cardiovascular disease can therefore be exacer-
bated by the adaptations that occur during gestation.19
Despite these concerns, pregnancy is well tolerated by
asymptomatic or mildly symptomatic women with HCM. The
hypertrophied LV can accommodate the rise in cardiac output
and blood volume, and the reduction of systemic vascular
resistance is generally without consequences on LV filling
pressures. Development of heart failure symptoms is uncom-
mon during pregnancy, occurring in <5% of patients with
previously asymptomatic HCM. The most common issues are
related to diastolic dysfunction, LV outflow tract (LVOT)
obstruction, and arrhythmias. In pregnant patients with HCM,
preexisting heart failure symptoms, pulmonary hypertension,
and severe LVOT obstruction are the main predictors of
maternal and neonatal events.20 Of note, multiple pregnan-
cies are not likely to affect the natural history of the disease,
nor its phenotypic expression.3
Demographic Features
Ethnicity
Epidemiological data in different ethnicities show that the
prevalence and clinical profile of HCM do not differ among
various populations.21 Because most of the studies address-
ing phenotypic expression and natural history of HCM are
based on white patients, data on individuals of other
ethnicities are limited. However, observations in athletes
and patients with hypertension reveal that individuals of
African/Afro-Caribbean descent show more significant mor-
phological changes, degree of LVH, and ECG abnormalities
compared with whites.22 Awareness of such differences is
important in order to avoid overdiagnosis of HCM in healthy
individuals exhibiting phenotypes that are within physiological
limits for their ethnicity. A recent study by Sheikh et al23
Table 1. Potential Environmental Modifiers of Phenotypic Expression in HCM
Phenotypic Expression Modifiers Effects
LVH Sex ↑ LVH in men
Ethnicity ↑ LVH in Afro-Caribbean athletes
Obesity ↑ LV mass in obese individuals
Hypertension ↑ LVH in patients with hypertension
Renal disease ↑ LVH in CKD
Sport No clear effects
Diet No clear effects
Microvascular dysfunction Hypertension ↑ Microvascular ischemia
Autoimmune disease ↑ Microvascular ischemia
CAD ↑ Microvascular and macrovascular ischemia
Cocaine abuse ↑ Microvascular and macrovascular ischemia
Thrombophilic status ↑ Microvascular and macrovascular ischemia
Hemodynamic status/obstruction Dehydration ↓ Venous return,↑ LV gradients
Anemia ↑ LV gradients
Thyroid disease ↑ LV gradients
Pregnancy ↓ LV gradients
Pharmacological treatment (inotropes, vasodilators, diuretics) ↑ LV gradients
Acquired valvular heart disease ↑↓ LV gradients
↑ indicates increased; ↓, decreased; CAD, coronary artery disease; CKD, chronic kidney disease; HCM, hypertrophic cardiomyopathy; LV, left ventricular; LVH, left ventricular hypertrophy.
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showed that black patients with HCM almost always exhibit
an abnormal ECG, with high prevalence of T-wave inversion;
moreover, black patients more often had apical or concentric
patterns of hypertrophy compared with white patients.
Although hypertension is more common in black individuals,
the greater burden of LVH does not appear related to
hypertension and probably rest on a polygenic basis. Indeed,
the morphological differences persisted after excluding
patients with hypertension and likely reflect a true impact of
ethnicity on the HCM phenotype. In the same study, black
patients did not exhibit a higher prevalence of conventional
risk markers for SCD, and ethnicity was not a determinant of
the composite primary outcome of death, cardiac arrest, or
appropriate implantable cardioverter-defibrillator therapy.
Sex
The Mendelian mode of HCM inheritance is autosomal
dominant, which implies that equal numbers of men and
women are carriers of the underlying disease-causing muta-
tion. However, men are consistently more prevalent in
published cohorts, typically with a 3:2 ratio to women.
Although male predominance may reflect a similar lack of
awareness that is well recorded in other cardiovascular
diseases in women, the difference in disease expression
among the sexes is likely to be influenced by genetic and
endocrine factors. Women with HCM are older at presenta-
tion, more symptomatic, and more likely to have resting LV
obstruction compared with men.24 While LV mass indexed for
body surface area is lower in women, suggesting milder
phenotypic expression25 (Figure 1), women are more prone to
heart failure–related mortality and HCM-related complica-
tions.26,27 Furthermore, women with HCM have comparable
rates of SCD compared with men,24,28,29 although they may
be less exposed to arrhythmic events triggered by strenuous
exercise.30,31 As women are less likely to be diagnosed with
HCM at routine medical examination, a higher index of
diagnostic suspicion and lower threshold for referral to a
specialist are warranted.
Little is known regarding the impact of sex hormones on
the development of myocardial hypertrophy in HCM, although
the older, often postmenopausal age at presentation in
women with HCM support a protective role of estrogens.
Indeed, estrogens are known to have a protective role in
secondary hypertrophic response, while exposure of cardiac
myocytes to androgens may result in LVH. In healthy
individuals, increase in cardiac mass following puberty is
greater in men, and estrogens have been shown to exert
preventive effects on cardiac hypertrophy.31 However, the
physiological actions of androgens in the heart remained
largely unclear compared with those of estrogens. Some
studies have shown that androgens are prohypertrophic,32,33
via a direct androgen receptors–mediated pathway. Further-
more, a study by Lind et al33 showed that variations at the
androgen receptor gene were associated with LVH in men
with HCM in a cohort of 200 unrelated patients. Experiments
in mouse models carrying MYBPC3 mutations showed
significant sex differences in terms of sarcomeric force
generation. These differences were even more evident in
mutant mice engaged in an exercise protocol, suggesting that
physiological stimuli elicit a sexually dimorphic cardiac
response.32
Habits and Lifestyle
Exercise and Sport
Regular exercise has a favorable effect on many of the
established risk factors for ischemic cardiovascular disease,
thereby decreasing morbidity and mortality.33–35 However,
strenuous exercise is known to trigger SCD in athletes with an
underlying cardiac disease.36,37 HCM is believed to be a
common cause of SCD in young athletes,38 and the interplay
of the pathological substrate characterized by myocardial
disarray, fibrosis, and microvascular remodeling with physio-
logical mechanical stressors and potentially adverse effects of
Figure 1. Sex differences in left ventricular (LV) mass in
patients with hypertrophic cardiomyopathy. Men exhibit signifi-
cantly higher values of indexed LV mass. Reprinted from Olivotto
et al25 with permission. Copyright ª2008, Elsevier.
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intense exercise such as dehydration, sympathetic stimula-
tion, electrolyte abnormalities, and acid base disturbances
may trigger fatal arrhythmias during exertion.39 Therefore,
consensus statements recommend that individuals with HCM
should refrain from participating in competitive physical
activity.40,41 These recommendations are based on reason-
able pathophysiological assumptions and are ultimately aimed
at protecting athletes by preventing SCD.
There are, however, several scientific, epidemiological, and
ethical matters of debate related to exercise participation in
patients with HCM. First, the rate of exercised-induced SCD in
HCM is unclear. Recent data suggest that SCD occurs during
sport in less than 20% of patients with a postmortem
diagnosis of HCM, and that young age and male sex are the
main independent variables associated with exercise-induced
SCD.42 Second, while HCM has been historically reported as
the most common cause of SCD in young athletes in the
United States, other conditions such as arrhythmogenic right
ventricular cardiomyopathy or sudden arrhythmic death
syndrome with a normal cardiac autopsy may be more
frequent.43–45 Furthermore, novel entities such as, unex-
plained or “idiopathic” LVH (ie, LVH without evidence of
significant myocardial disarray) has been reported as a
relatively common finding in athletes and nonathletes who
died suddenly.44,45 The significance of idiopathic LVH is
unclear and postulated theories range from part of the
spectrum of HCM, to trigger for fatal arrhythmias in individ-
uals with an underlying arrhythmogenic syndrome, because
LVH exacerbates electric instability. These data imply that the
epidemiologic burden of HCM as a cause of SCD in athletes
may be lower than previously reported.
Another important point of debate is whether long-term
exercise has a role in the natural history of HCM. There are no
data to support a detrimental effect of exercise in patients
with HCM and no evidence that long-term athletic training
may promote an exacerbation of the underlying disease
process. In animal models, routine exercise before the
development of cardiac phenotype prevented subsequent
fibrosis, myocyte disarray, and induction of markers of
hypertrophy in mutant myosin heavy chain mice.46 Con-
versely, in non-mutant rats conditioned to run vigorously for
up to 16 weeks, cardiac fibrosis, changes in ventricular
function, and increased arrhythmic propensity were
observed.47 To date, none of these effects have been
demonstrated in humans, and data on the effects of exercise
as a natural history modifier, as seen in arrhythmogenic
cardiomyopathy,34 are lacking in HCM.
Based on the plethora of benefits of moderate exercise for
the cardiovascular system and general well-being, recreational
exercise should be encouraged in most individuals with
HCM.37 At present, most patients are less active than the
general population and report purposefully reducing or even
stopping their activity after diagnosis,48 an attitude that is
likely to adversely affect their long-term outcome. A recent
randomized study showed that moderate-intensity exercise,
compared with usual activity, resulted in a significant increase
in exercise participation and capacity in patients with HCM,
without a significant increase in the burden of arrhythmias or
other adverse events.49 This study supports regular adoption
of aerobic training in HCM following the Greek philosophical
principle of Metron ariston (ie, moderation is best), based on
the tailoring of exercise activity to reasonable thresholds
based on age and fitness level.
Another important matter of debate is the management of
genotype positive–phenotype negative (G+/P) individuals, a
rapidly increasing population following the widespread adop-
tion of genetic testing. Often, individuals identified by this
term have no evidence of LVH but are not truly “phenotype
negative,” because of the presence of ancillary HCM mani-
festations such as LV crypts, mitral valve abnormalities, and
mild regional diastolic impairment at the septal level. Although
the European Society of Cardiology recommendation is
restrictive and states that athletes with a G+/P should
have the same limitations as patients with overt HCM, a
detrimental role of exercise in these individuals has not been
demonstrated,50 and their access to competitive sports is not
restricted in the United States.
Diet and Fluid Intake
The role of dietary habits is crucial to both the development
and prevention of cardiovascular disease. Diet and lifestyle
have been a main focus of research in coronary artery disease
(CAD) for decades.51 Benefits and harms of diet are not
limited to the mechanistic interactions underlying the pro-
gression of atherosclerosis but extend to other scenarios,
including primary cardiomyopathies. For example, a soy diet
was associated with progressive to severe end-stage car-
diomyopathy and heart failure in a transgenic mouse model of
a-myosin heavy chain HCM, possibly through induction of
augmented cell growth and apoptosis. Conversely, such
evolution was prevented by a casein diet.52 To date, however,
the impact of different dietary regimens on patients with HCM
has not been investigated.
In clinical practice, apart from the obvious implications
related to weight control and cardiovascular prevention,
dietary advice to patients with HCM should deal with the
effects of meals on quality of life and symptomatic status.
Following food intake, splanchnic blood flow sequestration
results in decreased circulating plasma volume, thereby
increasing LV outflow gradients.53,54 Thus, postprandial
symptoms of angina, dyspnea and—occasionally—syncope,
are common in obstructive HCM. Patients should be recom-
mended to avoid large meals and reduce levels of
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postprandial activity. Dehydration, which results in reduced
preload, increased contractility, and possibly a worsening of
dynamic LV obstruction should also be avoided. Finally,
alcohol should be consumed with moderation by patients with
HCM, as it has been shown to decrease arterial blood
pressure and increase systolic anterior motion severity and
degree of intraventricular obstruction55 (Figure 2).
Acquired Comorbidities
Hypertension
Hypertension is conventionally regarded as a potential
exclusion criterion for the diagnosis of HCM.3 However, many
patients with unequivocal HCM may present with or develop
some degree of hypertension, given the high prevalence of
hypertension in the adult population.56 In most patients with
hypertension, LV wall thickness is normal or only mildly
increased (≤13 mm). Only a minority of patients, often with
secondary forms of hypertension or of Afro-Caribbean or
African descent, have more substantial hypertrophy (up to
16 mm) and fall into a “grey zone” of potential overlap with
HCM.23 When differentiating hypertensive heart disease from
HCM, a number of additional features, including mitral valve
abnormalities and lack of extracardiac organ damage may be
suggestive of the latter.57
In a recent study, hypertension was an independent
predictor of outcome in patients with HCM, irrespective of
ethnicity, sex, or age.23 A significant increase in afterload and
neuroendocrine activation may further increase LV mass and
adversely affect the clinical expression of the disease.
Aggressive management of uncontrolled hypertension is
Figure 2. Alcohol and left ventricular (LV) obstruction in hypertrophic cardiomyopathy. After ethanol
ingestion the average LV gradients increase from an average of 38.1 to 62.2 mm Hg. Reprinted from
Paz et al55 with permission. Copyright ª1996, the Massachusetts Medical Society.
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therefore mandatory in HCM, but may be challenging, as most
vasodilators will exacerbate dynamic LVOT obstruction.58,59
The question of whether a quota of secondary LVH might
worsen the phenotypic expression of HCM in patients with
hypertension remains unresolved. Afterload increase and
neuroendocrine activation may plausibly contribute to an
augmented LV mass. Likewise, appropriate treatment of
hypertension might reduce “nongenetic” LVH. This intuitive
concept, although not proven, is supported by studies
showing regression of LVH following septal reduction thera-
pies. Of note, reduction of LV mass following resolution of
afterload mismatch occurred in regions of HCM hearts remote
from the septum, suggesting that reverse remodeling may
occur in this disease on removal of pathologic environmental
stimuli.60,61 This general concept of partial reversibility of LVH
in patients with HCM requires further investigation and is of
relevance to other potential determinants such as sport,
obesity, and renal failure.
Another interesting concept is that polymorphisms in the
renin-angiotensin-aldosterone system, which have been asso-
ciated with LVH in untreated hypertension, may be potential
disease modifiers in HCM.62 and may specifically impact the
clinical phenotype of HCM.63
Obesity
Obesity is a rising public health problem and a known risk
factor for cardiovascular diseases. Because of its maladaptive
effects on various cardiovascular risk factors and its adverse
effects on cardiac structure and function, obesity has a major
impact on morbidity and mortality. As recently demonstrated,
its prevalence in HCM is remarkably high, reaching almost
40%. Obesity is independently associated with increased LV
mass (Figure 3), an adverse prognostic factor in HCM,
contributing to more rapid clinical progression and worsening
of heart failure symptoms.64 Interestingly, however, LV mass
increase in obese patients with HCM seems to merely reflect
LV cavity enlargement, physiologically aimed at increasing
cardiac output65 to meet the increased requirements of
excessive body weight. Conversely, maximal LV thickness is
similar in normal weight versus obese patients with HCM,
suggesting that the genetic design of asymmetric septal LVH
is independent of body mass index.48 Of note, LV obstruction
is more common in obese patients and observed in more than
50% with body mass index >30, because of distinctively
higher predisposition to provocable (as opposed to resting)
gradients. A beneficial impact of weight reduction on the
severity of LVOT obstruction is plausible but remains
unproven.66 Finally, although the role of obesity as an
independent risk factors for SCD in HCM has not been
established, the susceptibility of obese patients with HCM to
fatal arrhythmias is a potential area of research.67
Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a common condition in
Western countries, characterized by repetitive interruption of
ventilation and hypoxia during sleep, which affects a large
proportion of patients with hypertension, obesity, CAD, atrial
fibrillation, and stroke. In peripheral OSA this is caused by
collapse of the pharyngeal airway, while central OSA is related
to malfunction of the respiratory control centers in the
brainstem.
In recent years there have been rapid advances in the
understanding of the relationship between OSA and cardio-
vascular disease, including HCM.68 OSA has been reported in
up to 70% of patients with HCM.69 LVOT obstruction is
Figure 3. Relationship between left ventricular (LV) mass and
body mass index (BMI) (A) and LV mass indexed for body surface
area and BMI (B) in patients with hypertrophic cardiomyopathy.
Obese individuals (BMI >30) exhibit higher values of LV mass and
indexed LV mass. Reprinted from Olivotto et al64 with permission.
Copyright ª2013, Elsevier.
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generally exacerbated by sympathetic stimulation, and the
nocturnal hypoxia-induced hyperadrenergic state characteris-
tic of OSA would be expected to worsen the hemodynamics of
HCM. This vicious pathophysiological cycle translates into
increased symptom burden during the day. Furthermore,
peripheral vasoconstriction, apnea-induced hypoxemia, car-
bon dioxide retention, renal retention of salt and water, and
increased renin-angiotensin-aldosterone activity may con-
tribute to arrhythmogenesis in an already vulnerable patho-
logical substrate.70 Whether OSA is associated with a higher
rate of ventricular arrhythmias or SCD and in general with
adverse prognosis in HCM remains unclear. Nevertheless,
treatment of sleep apnea, whether by weight loss, continuous
positive airway pressure, or postural therapy provides impor-
tant benefit in the general population and should be sought in
patients with HCM.
Coronary Artery Disease
Myocardial ischemia is often observed in patients with HCM,
occurring at the microvascular level as a result of structural
abnormalities of the intramural coronary arterioles, charac-
terized by thickening of the intima and medial layers of the
vessel wall associated with decreased luminal cross-sectional
area.71,72 Adult patients with HCM are not immune from
epicardial CAD, which may be difficult to diagnose, given the
high frequency of microvascular angina and the striking ECG
repolarization abnormalities present at rest, which hinder the
interpretation of exercise ECG testing. Concomitant
atherosclerotic disease has an important impact on the
natural course of HCM. Given the increased myocardial mass
and high myocardial oxygen demand, patients with HCM are
particularly susceptible to the additional ischemic burden of
one or multiple epicardial coronary artery stenosis.73 Not
unexpectedly, CAD is a major prognostic indicator in HCM and
is associated with an increase in overall mortality, SCD, and
cardiac events, with a synergistic rather than additive effect.56
Preventive strategies for atherosclerotic disease should
always be considered in patients with HCM and the standards
for control of modifiable cardiovascular risk factors should
arguably reflect those used for secondary rather than primary
prevention of CAD because of the intrinsic frailty of the HCM
myocardium to ischemic insults.
Myocardial bridging is a rare but modifiable mechanism of
ischemia, acute myocardial infarction, and even SCD in
young patients with HCM.74 Myocardial bridging occurs when
the epicardial coronary arteries, usually the proximal left
anterior descending artery, are intramyocardial, resulting in
systolic compression of a coronary artery on coronary
angiography. While bridging also occurs in normal healthy
controls, it is much more common in patients with HCM,
reaching a prevalence of 30% to 40%. Because only a fraction
of these lesions have been associated with SCD, generally in
children, the role of bridging as a risk predictor in adult
patients is debated but probably limited. Only when associ-
ated with clear hemodynamic abnormalities and symptoms,
myocardial bridging should be treated with a surgical
deroofing procedure.75
Sarcomere Protein Gene Profile and
Predisposition to Cardiac Disease
Sarcomere gene mutations have been identified in the general
population by large-scale screening studies. Most carriers do
not have a cardiomyopathy and may express no or only mild
and nonspecific phenotypic stigmata. However, these variants
seem to retain a generic capacity to trigger cardiac disease in
the presence of environmental stimuli, creating a sort of
nonspecific frailty of the myocardium. In a landmark study, a
common 25 mb MYBPC3 deletion was associated with
increased risk of heart failure in South Asians exposed to
secondary risk factors, such as hypertension and hyperc-
holesterolemia, posing a lifelong threat to carriers.76 Further-
more, a role for truncating titin mutations has been recently
proposed in the development of peripartum cardiomyopa-
thy,77 suggesting the possible interaction between a genetic
predisposition and additional environmental (pregnancy) or
genetic stimuli. These observations add a broader dimension
to the interactions between cardiomyopathies and the
environment: from relatively uncommon, genetically driven
diseases that are only modestly influenced by external stimuli,
to a common genetic trait that is not pathogenic per se, but
may provide predisposition to cardiac disease in the presence
of risk factors and high-risk lifestyles (Figure 4). Understand-
ing these complex interactions may prove critical to the
identification of novel therapeutic targets for cardiovascular
disease in the future.
Conclusions
Our genetic destiny is hardly written in stone. Virtually all
human diseases result from the interaction of genetic
susceptibility factors with modifiable environmental influ-
ences. When we observe that even “classic” inherited
diseases can be modified by environmental conditions, it
becomes clear that the relationship between the two is much
more complex than a simple one gene–one disease model
linear relationship. HCM is not an exception to this general
rule. Overall, however, physiological stimuli and comorbidities
seem to exert a modest impact especially on the phenotypic
expression of HCM. Future research targeting HCM variability
should rather focus on molecular aspects including modifier
genes, epigenetic factors, and the role of regulatory systems
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such as microRNAs, the ubiquitine-proteasome complex, or
nonsense-mediated RNA decay.78,79
Nevertheless, identifying modifiable risk factors that may
aggravate HCM phenotype and the clinical course remains
important in clinical practice, even in the absence of specific
studies, along the general principles of contemporary cardio-
vascular medicine. Because of the intrinsic fragility of HCM
hearts, it may be reasonable to manage patients according to
the standards of established atherosclerotic disease, ie, of
secondary rather than primary cardiovascular prevention,
including strict targets for lipid profile, blood pressure and
weight control, and lifestyle advice including appropriate
exercise and diet (Table 2).
In the era of evidence-based medicine, the conundrum
behind gene-environment interactions in genetic inherited
cardiac diseases should be unraveled through improved
access to empiric knowledge from randomized control trials,
as well as, increasingly, from “Big Data.”80 Extensive
research is warranted to identify environmental factors that
may effectively act as natural history modifiers. Only through
a deepened understanding of this interplay we will be able
to address the many questions related to the extreme
heterogeneity of clinical expression and natural history of
HCM.
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Figure 4. Continuum between genetic predisposition and environmental influences in hypertrophic
cardiomyopathy. Multiple variants usually have a severe phenotypic expression that is less likely to be
dependent from environment, while, in individuals harboring a single mutation, the effect of other acquired
conditions may be more relevant. Multiple variants, each with small effect size, may interact with
nongenetic factors to produce a hypertrophic cardiomyopathy phenotype. Genetic variants recognized as
pathogenic may be present in healthy individuals where the phenotypic expression emerges only after the
interaction with a specific environmental factor. CAD indicates coronary artery disease; OSA, obstructive
sleep apnea.
Table 2. Proposed Management of Modifiable Risk Factors in
Patients With HCM
Lifestyle/Clinical
Variables Possible Effects
LDL <100 mg/
dL*
↓ Risk of CAD and myocardial ischemia
BP <130/
80 mm Hg*
↓ Risk of secondary LVH caused by increased
afterload
Moderate
exercise
Improvement in diastolic function and exercise
capacity
↓ Risk of obesity
Weight
management
↓ Risk of obesity
↓ Risk of development of a more marked LVH
caused by increased afterload
↓ indicates decreased; BP, blood pressure; HCM, hypertrophic cardiomyopathy; LDL, low-
density lipoprotein; LVH, left ventricular hypertrophy.
*The standards for control of modifiable cardiovascular risk factors should arguably
recapitulate those used for secondary prevention in patients with coronary artery
disease (CAD), in all genetic cardiomyopathies, based on the principle that superimposed
atherosclerotic disease seems to have synergistic rather than additive effects.
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